Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) in Patients with Concomitant Atrial Fibrillation and Heart Failure: A Systemic Review and Meta-Analysis of Randomized Trials
Why the study?
Do Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) improve efficacy and safety in patients with concomitant atrial fibrillation and heart failure compared to warfarin?
Population
Patients with concomitant atrial fibrillation (AF) and heart failure (HF)
Comparison
Non-Vitamin K Antagonist Oral Anticoagulants… vs Warfarin
Design
Meta-analysis
Authors
Discussion
Loading...
Member takes
Implication
Single-/high-dose NOACs preferred over warfarin in AF with HF; extends meta-analytic evidence to this high-risk subgroup.
Structured PICO
Do Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) improve efficacy and safety in patients with concomitant atrial fibrillation and heart failure compared to warfarin?
P
Population
Patients with concomitant atrial fibrillation (AF) and heart failure (HF)
I
Intervention
Non-Vitamin K Antagonist Oral Anticoagulants (NOACs), including single-/high-dose and low-dose regimens
C
Comparator
Warfarin
O
Outcome
Efficacy and safety profile
In patients with concomitant atrial fibrillation and heart failure, single- or high-dose NOACs provide superior efficacy and safety compared to warfarin.
Cite This Study
Xiong et al. (2015) studied this question.